Eli Lilly: It Is A Bet On Human Longevity

Eli Lilly's recent stock dip presents a compelling buying opportunity, with valuation multiples returning to 2022 levels despite a 45% YoY revenue surge driven by blockbuster drugs Mounjaro and Zepbound. The company's deep and innovative pipeline, including a potential oral GLP-1 and gene therapy, positions it strongly to capitalize on the global aging trend, supporting a 'Buy' rating and potential 20% upside for long-term investors.

Analysis

Eli Lilly's recent share price decline has brought its valuation multiples to levels not seen since 2022, creating a potential dislocation from its strong operational performance. The company's revenue surged 45% year-over-year, propelled by the blockbuster success of its drugs Mounjaro and Zepbound. Despite near-term headwinds from Pharmacy Benefit Managers (PBMs), these are considered manageable given the drugs' superior clinical data and substantial market demand. The future growth outlook is further supported by a deep innovation pipeline, which includes a potential oral GLP-1 drug (orforglipron) and a strategic gene therapy acquisition through Verve aimed at heart disease. This long-term strategy aligns with powerful secular trends, such as the global aging population identified by UBS's "Longevity" theme, suggesting sustained demand for Lilly's chronic disease treatments.

Key Decisions for Investors

• Given the stock's return to 2022 valuation multiples despite a 45% YoY revenue surge, long-term investors could consider the current price an attractive entry point.
• Monitor the sales momentum of Mounjaro and Zepbound, as their continued performance is critical to justifying the growth outlook and offsetting any near-term PBM pressures.
• Track milestones within the R&D pipeline, specifically progress on the oral GLP-1 candidate (orforglipron) and the Verve gene therapy platform, as these represent significant long-term growth catalysts beyond the current product cycle.